RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Harness Therapeutics
Seed Round in 2022
Transine Therapeutics
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of CAR T-cell therapies that produce a better and more durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Lunac Therapeutics
Venture Round in 2021
Lunac Therapeutics is a UK-based drug discovery company.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics.
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Lunac Therapeutics
Series A in 2019
Lunac Therapeutics is a UK-based drug discovery company.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
AdoRx Therapeutics Limited is a drug discovery company based in Edinburgh, United Kingdom, focused on developing new therapeutics for cancer by modulating the adenosine pathway. Founded in 2017, the company targets the high levels of adenosine present in the tumor microenvironment, which allow cancer cells to evade the immune system. AdoRx's lead programs concentrate on creating tailored adenosine receptor antagonists designed to counteract the effects of elevated adenosine levels. The leadership team at AdoRx has extensive experience in drug discovery, having previously developed over 25 clinical candidates. The company is supported by investment from Epidarex Capital and Sixth Element Capital, enhancing its capacity to advance innovative cancer treatments.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom. Founded in June 2012, the company specializes in the research and development of innovative drugs aimed at treating dietary-related metabolic diseases, which have seen a significant rise in prevalence over recent decades. Eternygen focuses on small molecule inhibitors targeting the sodium-coupled citrate transporter (NaCT), a crucial regulator of lipid metabolism linked to conditions such as fatty liver, diabetes, and obesity. By addressing the underlying metabolic failures associated with these diseases, Eternygen aims to develop safe and effective therapies that can enhance patient care in managing these widespread health issues.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Mironid Limited is a drug discovery company focused on developing therapeutic candidates aimed at treating degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014 and based in Newhouse, United Kingdom, Mironid employs a unique Physiology Mirroring Approach to design assays that replicate the drug target's conformation and environment found in living cells. The company's pipeline features Novel ShoLo compounds for chronic inflammatory diseases and Novel LoAc compounds for degenerative kidney diseases. By modulating the activity of key cell signaling proteins, Mironid aims to create high-value therapeutics that address significant unmet medical needs, thereby enhancing the health and quality of life for patients.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.
Funderbeam is an equity crowdfunding platform established in 2013, with its main office in Tallinn, Estonia, and a subsidiary based in Zagreb, Croatia. It offers a unique marketplace for early-stage investments, allowing investors to buy and sell equity stakes in private companies. Utilizing blockchain technology, Funderbeam provides transparency and security in transactions, enabling founders to raise capital while granting early-stage investors access to liquidity. The platform serves as a vital resource for high-growth private companies by facilitating investment opportunities and helping clients manage their private market portfolios. Through its innovative approach, Funderbeam has positioned itself as a significant player in the global startup ecosystem.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Sirakoss Ltd. is a medical device company based in Edinburgh, United Kingdom, established in 2010. The company specializes in the development of synthetic bone graft substitutes, particularly its proprietary MaxSi Graft technology, which is available in granular and putty forms. These products are designed for various medical applications, including trauma, spine, craniomaxillofacial, and dental procedures. Sirakoss's innovative solutions aim to facilitate the treatment of bone defects and fusions, enabling efficient recovery for patients with congenital or degenerative conditions. As of November 2020, Sirakoss operates as a subsidiary of OssDsign AB.
Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.